Details of Drug-Drug Interaction
| Drug General Information (ID: DDIOQ5BWDY) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Daptomycin | Drug Info | Fluvastatin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antibiotics | Statins/Antihyperlipidemic Agents | |||||||
| Structure | |||||||||
| Mechanism of Daptomycin-Fluvastatin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Daptomycin | Fluvastatin | |||||||
| Mechanism | Rhabdomyolysis | Rhabdomyolysis | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Adverse reactions | ||||||||
| Factor Description | An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Use of HMG-CoA reductase inhibitors should be temporarily suspended in patients receiving daptomycin. All patients receiving daptomycin should be monitored for the development of muscle pain or weakness, particularly of the distal extremities. CPK levels should be monitored weekly, and patients who develop unexplained elevations in CPK should be monitored more frequently. Daptomycin should be discontinued in patients with unexplained signs and symptoms of myopathy in conjunction with CPK levels exceeding 1000 U/L (approximately 5 times the upper limit of normal), or in patients without reported symptoms who have marked elevations in CPK (10 times the upper limit of normal, or more). | ||||||||
